Navigation Links
BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types

SAN FRANCISCO, Oct. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced molecular biomarker data demonstrating the overexpression of the PARP (poly-ADP-ribose polymerase) protein in multiple cancers, including ovarian, breast and lung tumors. The research is the first demonstration of PARP overexpression in specific types of cancer. This insight is being used to guide the clinical development of the company's pipeline of PARP inhibitor candidates.

The results were presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.

"These results allow us to focus our clinical development plan for BSI-201 by targeting tumors types that have the greatest probability of clinical success," said BiPar Executive Vice President Barry Sherman, M.D.

BiPar researchers used the Gene Logic Inc. BioExpress(R) System database to analyze PARP-1 gene expression in all types of primary human cancer and compared the results to normal counterpart tissue. PARP expression was above the 95 percent upper confidence limit for normal tissue in ovarian cancer, intraductal breast cancer, lung cancer and uterine cancer. In contrast, prostate tumor tissue showed minimal PARP overexpression.

BSI-201 has been tested as both monotherapy and in combination with standard therapy in Phase 1 studies in patients with solid tumors. BiPar is preparing to initiate Phase 1b and Phase 2 trials of BSI-201 in several specific tumor types guided largely by gene expression data.

About PARP

PARP-1 plays a central role in cell proliferation and in DNA repair. BiPar's novel, proprietary PARP inhibitors are a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical studies suggest the drugs selectively inhibit cell proliferation and are active against a broad range of tumor types.

About BiPar Sciences

BiPar Sciences Inc. ( is a clinical-stage biopharmaceutical company developing and commercializing a pipeline of novel, tumor-selective drugs designed to meet the significant unmet needs of cancer patients.

BioExpress(R) is a registered trademark of Gene Logic Inc.

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
2. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
5. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
6. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
7. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
10. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
11. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Building on its 25-year ... Johnson (NYSE: JNJ ) today announced four ... to significantly reduce the burden of HIV incidence, ... percent of new HIV infections among adolescents in ... Day, these new initiatives include collaborations with the ...
(Date:12/1/2015)... York , December 1, 2015 /PRNewswire/ ... Pills, Contraceptive Injectables, Topical Contraceptives, Male Condoms, ... Contraceptive Vaginal Rings, Contraceptive Diaphragms, Contraceptive Sponges, ... Analysis, Size, Share, Growth, Trends and Forecast ... by Transparency Market Research (TMR).The report states ...
(Date:12/1/2015)... ATLANTA , Dec. 1, 2015   ... automated value cycle solutions, today announced the company ... Pharmacy ChargeLink ® solution at ... 2015 Midyear Clinical Meeting . The new features ... complicated process of monitoring and managing enterprise-wide pharmacy ...
Breaking Medicine Technology:
(Date:12/1/2015)... FL (PRWEB) , ... December 01, 2015 , ... ... announces the Multi Jar, a container patent that allows for easier packing and organizing ... the US is worth $90 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:12/1/2015)... ... ... Hospital Tampa is the first health care provider in the region to offer the ... is a vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult ... least 40 to 45 kg, or a BMI of at least 35 to 39.9 kg ...
(Date:12/1/2015)... Houston, TX (PRWEB) , ... December 01, 2015 , ... ... owner of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best ... best of the best among the many elite aesthetic physicians honored by the industry ...
(Date:12/1/2015)... Delaware (PRWEB) , ... December 01, 2015 , ... ... winner at the 7th Annual 2015 Golden Bridge Business Awards under the New ... is a zero capex web based sample management software that helps ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays ... film for accurate interpretation by the radiologist. The marking utensils are so small, ... Calif., has found a way to alleviate this problem. , He developed the ...
Breaking Medicine News(10 mins):